618072-74-5

Upstream product

• 219562-56-8 D-4,5-O-(1-methylethylidene)-3,6-bis-O-(phenylmethyl)-myo-inositol 
• 618072-72-3 C₃₇H₃₆O₈ 
• 438035-30-4 D-4,5-O-(1-methylethylidene)-3,6-bis-O-(phenylmethyl)-scyllo-inositol 1-monobenzoate 
• 371155-65-6 (3aR,4S,7S,7aR)-3a,4,7,7a-tetrahydro-2,2-dimethyl-1,3-benzodioxole-4,7-diol 
• 266682-75-1 (3aR,4S,7S,7aR)-3a,4,7,7a-tetrahydro-2,2-dimethyl-4,7-di-O-benzyl-2,3-benzodioxole-4,7-diol 

Relevant academic research and scientific papers

INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME

The invented inositol and trehalose derivatives, prepared by introducing multiple units of the guanidine group to the backbone molecules, show excellent blood-brain barrier permeability, and accordingly, it can be easily transported to the brain tissues and utilized for the treatment of neurodegenerative diseases such as Alzheimer?s disease and Huntington's disease.

Synthesis of three enantiomeric pairs of scyllo-inositol phosphate and molecular interactions between all possible regioisomers of scyllo-inositol phosphate and inositol 1,4,5-trisphosphate 3-kinase

scyllo-Inositol phosphates, which are among the stereoisomers of myo-inositol phosphate, can have 15 possible regioisomers including three enantiomeric pairs: scyllo-I(1,2)P2, scyllo-I(1,2,4)P3, scyllo-I(1,2,3,4)P4. We her